Skip to main content

Entera Bio Ltd.

ENTX
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001638097

No open-market purchases or sales by Entera Bio Ltd. insiders were filed in the last 90 days; 27 institutions reported holding it in 13F filings for Q2 2026, worth $19.0M in total; no superinvestor holds it.

Q2 2021 vs. Q1 2021

How the institutions holding Entera Bio Ltd. changed between Q1 2021 and Q2 2021.

All holders in Q2 2021All holders in Q1 2021

13F holders of ENTX: Q1 2021 compared with Q2 2021
MeasureQ1 2021Q2 2021Change
Holders814+6
Shares1.99M5.11M+3.13M (+157.4%)
Value$7.57M$30.6M+$23.0M (+303.9%)

New holders (9)

Institutions that held Entera Bio Ltd. at the end of Q2 2021 but not at the end of Q1 2021.

Institutions new to ENTX in Q2 2021
InstitutionSharesValue% of portfolio
Ra Capital Management, L.P.2,353,000$14.1M0.23%
Citadel Advisors LLC67,170$402.0K0.00%
Susquehanna International Group, LLP66,733$399.0K0.00%
Verition Fund Management LLC30,523$183.0K0.00%
Geode Capital Management, LLC17,597$105.0K0.00%
Simplex Trading, LLC15,742$94.0K0.00%
Susquehanna Fundamental Investments, LLC14,400$86.0K0.00%
Cutler Group LP4,600$27.0K0.00%
Morgan Stanley2,190$13.0K0.00%

Sold out (3)

Institutions that held Entera Bio Ltd. at the end of Q1 2021 and filed for Q2 2021 without it.

Institutions that sold out of ENTX in Q2 2021
InstitutionShares, Q1 2021Value, Q1 2021
Renaissance Technologies LLC120,407$459.0K
Clearstead Advisors, LLC500$2.00K
Allworth Financial LP100$0